Diffuse Large B-Cell Lymphoma
Showing 1 - 25 of 231
Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)
Recruiting
- Diffuse Large B-cell Lymphoma
- Metabolically Armed CD19 CAR-T cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023
High-Dose Methotrexate Clearance in Diffuse Large B-Cell
Recruiting
- Central Nervous System Lymphoma
- Diffuse Large B-Cell Lymphoma
- Non-Interventional Study
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Sep 8, 2023
Diffuse Large B-cell Lymphoma Trial in Changchun (Mitoxantrone HCl liposome injection, RiTUXimab Injection, Cyclophosphamid)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Mitoxantrone hydrochloride liposome injection
- +4 more
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Aug 15, 2023
DLBCL Trial (Polatuzumab Vedotin)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Polatuzumab Vedotin
- (no location specified)
Jul 12, 2023
DLBCL Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Jul 11, 2023
Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:
Completed
- Diffuse Large B-cell Lymphoma
-
East Hanover, New JerseyNovartis
Jun 16, 2023
DLBCL Trial (maplirpacept (PF-07901801), Glofitamab, Obinutuzumab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- maplirpacept (PF-07901801)
- +2 more
- (no location specified)
May 30, 2023
Tafasitamab in Combination With Lenalidomide in Patients withR/R
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Tafasitamab Injection
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
May 31, 2023
DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Mitoxantrone Hydrochloride Liposome Injection
-
Jinan, Shandong, ChinaAffiliated Cancer Hospital of Shandong First Medical University
May 16, 2023
DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Chidamide
- +3 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Apr 10, 2023
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +7 more
- (no location specified)
Mar 23, 2023
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +4 more
- (no location specified)
Mar 9, 2023
Diffuse Large B-cell Lymphoma Trial in Hefei (Metabolically Armed CD19 CAR-T cells)
Recruiting
- Diffuse Large B-cell Lymphoma
- Metabolically Armed CD19 CAR-T cells
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Feb 9, 2023
DLBCL Trial in Worldwide (Polatuzumab Vedotin, Rituximab, Gemcitabine)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Polatuzumab Vedotin
- +3 more
-
Hollywood, Florida
- +89 more
Jan 31, 2023
DLBCL Trial in Worldwide (Epcoritamab, Cyclophosphamide, Rituximab)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Epcoritamab
- +5 more
-
Birmingham, Alabama
- +376 more
Jan 30, 2023
Diffuse Large B-cell Lymphoma Trial in Tampa, Philadelphia (Tisagenlecleucel, Ibrutinib)
Terminated
- Diffuse Large B-cell Lymphoma
- Tisagenlecleucel
- Ibrutinib
-
Tampa, Florida
- +1 more
Jan 27, 2023
CNS Lymphoma, DLBCL Trial in United States (Lenalidomide, Methotrexate, Nivolumab)
Recruiting
- Central Nervous System Lymphoma
- Diffuse Large B-Cell Lymphoma
- Lenalidomide
- +3 more
-
Los Angeles, California
- +42 more
Jan 26, 2023
DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- PF-07901801
- +2 more
-
San Juan, Puerto RicoAuxilio Mutuo Cancer Center
Jan 19, 2023
Chidamide in Recurrent and Refractory Diffuse Large b
Enrolling by invitation
- Diffuse Large B-cell Lymphoma
- Chidamide
- +2 more
-
Suzhou, Jiangsu, ChinaSecond Affiliated Hospital of Soochow University
Jan 9, 2023
Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Trial in United States
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +14 more
- Cholecalciferol
- Laboratory Biomarker Analysis
-
Scottsdale, Arizona
- +4 more
Jan 16, 2023
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Zilovertamab vedotin)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +11 more
- Zilovertamab vedotin
-
Duarte, California
- +13 more
Jan 12, 2023
DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Axicabtagene Ciloleucel
- +10 more
- (no location specified)
Jan 13, 2023